News

June 06, 2023

Carmot Therapeutics Appoints Michael Gray as Chief Financial Officer and Chief Operating Officer

May 25, 2023

Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes

May 23, 2023

Carmot Therapeutics to Present Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions

January 05, 2023

Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease

September 21, 2022

Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO

July 26, 2022

Carmot Therapeutics closes $160 million Series D financing to advance clinical pipeline of novel incretin receptor modulators

March 01, 2022

Carmot announces Tim Garnett M.D., previously Chief Medical Officer Eli Lilly, joins Carmot’s Board of Directors.

June 29, 2021

Carmot to receive royalty payments upon sales of Amgen’s FDA approved first-in-class KRAS G12C Inhibitor, LUMAKRAS™ (sotorasib); Further demonstrates the value of Carmot’s therapeutic platform

June 24, 2021

Carmot Therapeutics Initiates the Clinical Program for CT-388, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Patients with Type 2 Diabetes and Showcases its Technology at the Upcoming American Diabetes Association Scientific Session

May 04, 2021

Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 Diabetes